Biomet Report issue

For profit Phase 1 Phase 4
Founded: Bridgend United Kingdom (1977)
Status: Acquired by Zimmer Biomet (2014)

Organization Overview

First Clinical Trial
2008
NCT00675779
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biomet Biologics, LLC | Biomet Nederland BV | Biomet Polska Sp. z.o.o. | Biomet Spine

Active Ingredients

Drugs in Phase 4 Trials (2)

bone matrix (1 trial)

l-prp (1 trial)

Drugs in Phase 1 Trials (1)

autologous protein solution (1 trial)

Drugs in Other Trials (3)

atorvastatin (lipitor) (1 trial)

desogestrel (Mercilon) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fasciitis (Phase 4)

Fasciitis, Plantar (Phase 4)

Intervertebral Disc Degeneration (Phase 4)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6